Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividends for its preferred stockholders. The company will distribute $0.53906 per share to holders of 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) and $0.52344 per depositary share to holders of 8.375% Series B Cumulative Perpetual Preferred Stock (XOMAO). Both dividends will be paid on January 15, 2025, to shareholders of record as of January 3, 2025.
XOMA Royalty has acquired Pulmokine for $20 million, gaining rights to seralutinib, a Phase 3 asset being developed for pulmonary arterial hypertension (PAH). The acquisition adds seralutinib as XOMA's seventh Phase 3 royalty asset, complementing its six commercial royalty assets. Seralutinib is being co-developed by Gossamer Bio and Chiesi Farmaceutici, with Phase 3 study results expected in Q4 2025. Through this acquisition, XOMA stands to receive up to $25 million in milestone payments and earn a low to mid-single digit royalty on commercial sales.
XOMA Royalty reported Q3 2024 financial results with total income of $7.2 million, including $6.5 million from commercial products. Cash receipts totaled $9.9 million in Q3 and $42.3 million for the first nine months of 2024. The company recorded a net loss of $17.2 million, primarily due to a $14.0 million non-cash impairment related to Agenus. Notable events include FDA approval of MIPLYFFA™ for Niemann-Pick disease Type C and acquisition of 50% economic interest in TWIST Bioscience's portfolio of 60-plus licensed early-stage assets. Cash position stood at $146.8 million as of September 30, 2024.
Twist Bioscience (NASDAQ: TWST) has entered into a royalty purchase agreement with XOMA Royalty (NASDAQ: XOMA). Under the agreement, XOMA Royalty will provide Twist with an upfront payment of $15 million in exchange for the right to receive half of the future potential milestone and royalty payments from Twist's existing antibody discovery and biopharma services collaborations.
Twist will retain all upfront, service, and other revenue from these collaborations, as well as full rights to future biopharma collaborations with milestone and royalty terms. The agreement does not apply to synbio, NGS, or data storage revenue. This deal aims to provide Twist with immediate capital to support continued innovation and profitable growth across the company.
XOMA Royalty announced that Zevra Therapeutics has received FDA approval for MIPLYFFA™ (arimoclomol), the first therapy approved for use in patients with Niemann-Pick Disease Type C (NPC). MIPLYFFA™ is approved for use in combination with miglustat to treat neurological manifestations of NPC in patients two years and older.
XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones. This approval marks MIPLYFFA™ as the sixth commercial asset in XOMA Royalty's portfolio. In June 2023, XOMA Royalty acquired these rights from LadRx for a $5 million upfront payment plus a share of future event-based milestones.
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share. Holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per depositary share. The dividends will be paid on or about October 15, 2024, to holders of record as of the close of business on October 3, 2024. This announcement demonstrates XOMA's commitment to providing returns to its preferred stockholders.
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in two major investor conferences in September 2024. The company's executive team, including CEO Owen Hughes and CIO Brad Sitko, will present corporate overviews at:
1. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (September 9-11, 2024). Presentation scheduled for September 9 at 9:00 AM ET.
2. The 2024 Cantor Global Healthcare Conference in New York, NY (September 17-19, 2024). Presentation scheduled for September 17 at 2:30 PM ET.
Both presentations will be accessible via provided links and through XOMA's investor relations website. Replays will be available for 90 days after each event.
XOMA Royalty (NASDAQ: XOMA) reported its second quarter 2024 financial results and highlighted recent activities. Key points include:
- Cash receipts totaled $22.6 million in Q2 2024, including royalty income and milestones
- Expanded commercial royalty portfolio with acquisition of interests in XACIATO™ and two Phase 3 assets
- Completed acquisition of Kinnate Pharmaceuticals, adding potential royalty streams and over $9.5 million in capital
- FDA approved Day One's OJEMDA™, becoming XOMA's fifth commercial royalty
- Recorded total income and revenues of $11.1 million for Q2 2024
- Reported net income of $16.0 million for Q2 2024, compared to a net loss of $5.4 million in Q2 2023
- Cash and cash equivalents of $149.9 million as of June 30, 2024
XOMA (Nasdaq: XOMA) has announced that its Board of Directors has approved quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock.
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive a dividend of $0.53906 per share. Holders of depositary shares representing 1/1000 of a share of the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will get a dividend of $0.52344 per depositary share.
These dividends are scheduled to be paid on or about July 15, 2024, to shareholders of record as of July 3, 2024.
XOMA (NASDAQ: XOMA) announced an $8.1 million milestone payment from Viracta Therapeutics. This is linked to Day One Biopharmaceuticals' sale of its Priority Review Voucher (PRV) for $108 million. OJEMDA™, the only approved therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), has contributed to this milestone. XOMA's CEO, Owen Hughes, highlighted that the milestone has more than covered their initial $13.5 million investment made in March 2021. They expect future royalties from OJEMDA™ to enhance their royalty portfolio and generate sustainable cash flow.